Showing results (1051-1060 of 1,136) with videos related to

Sort By:
Pageof 114
Nature Communications|October 16, 2020
Cardio-centric hemodynamic management improves spinal cord oxygenation and mitigates hemorrhage in acute spinal cord injuryAlexandra M Williams, Neda Manouchehri, Erin Erskine, et al.
Journal of Intensive Care Medicine|December 13, 2021
Bag-Mask Ventilation Versus Apneic Oxygenation During Tracheal Intubation in Critically Ill Adults: A Secondary Analysis of 2 Randomized TrialsErin M Vaughan, Kevin P Seitz, David R Janz, et al.
Toxicology and Applied Pharmacology|September 20, 2011
Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomicsN C Kleinstreuer, A M Smith, P R West, et al.
Drug Development and Industrial Pharmacy|November 6, 2018
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeysJ Scott Crowe, Kevin J Roberts, Timothy M Carlton, et al.
Osteoarthritis Imaging|February 12, 2024
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With OsteoarthritisAli Guermazi, Frank W Roemer, Andrew J Kompel, et al.
The Journal of Pathology|August 29, 2012
The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancerJaeline E Spowart, Katelin N Townsend, Hassan Huwait, et al.
Osteoarthritis and Cartilage|August 31, 2023
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumabJohn A Carrino, Timothy E McAlindon, Tom J Schnitzer, et al.
Thorax|February 28, 2024
Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individualsDebananda Gogoi, Howard Yu, Michelle Casey, et al.
Scientific Reports|October 3, 2019
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis PatientsSuhail Nurbhai, Kevin J Roberts, Timothy M Carlton, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 4, 2021
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized TrialMarc C Hochberg, John A Carrino, Thomas J Schnitzer, et al.
Pageof 114